

an inherent "evaluating growth of the tumor." The dependent claims have been stylistically amended to avoid excess verbiage. Other than reciting the targeted metastatic prostate tumor cells, these amendments do not change the scope of the claims. These amendments introduce no new matter.


*35USC112, first paragraph - enablement*

The claims have been restricted to targeting a particular type of tumor, a metastatic prostate tumor. Effective targeting of this tumor type is specifically exemplified in Examples III and IV, p.18, line 17 - p.25, line 9. Note that the exemplified therapy includes the specific limitations of claims 25 and 35, wherein the administered agent comprises a plurality of non-covalently linked NKG2D-binding moieties of a natural MICA, MICB or ULBP NKG2D ligand, restricted to a common presenting surface of a host-compatible cell transformed to express the binding moieties (see, e.g. p.19, lines 20-26). As such, the claims are limited to targeting a particular tumor type. Furthermore, the claims require a resultant inhibition of tumor growth; hence, the targeted metastatic prostate tumor type is further functionally limited to those susceptible to the subject method.

The Examiner is invited to call the undersigned if she would like to amend the claims to clarify the foregoing or seeks further clarification of the claim language.

We petition for and authorize charging our Deposit Account No.19-0750 all necessary extensions of time. The Commissioner is authorized to charge any fees or credit any overcharges relating to this communication to our Dep. Acct. No.19-0750 (order B01-088-1).

Respectfully submitted,  
SCIENCE & TECHNOLOGY LAW GROUP



Richard Aron Osman, Ph.D., Reg. No. 36,627  
Tel: (650) 343-4341; Fax: (650)343-4342

"To Help Our Customers Get Patents"  
Mission Statement, USPTO External Customer Services Guide